Drug reference directory
Drug reference

iron isomaltoside

Parenteral Iron Supplement · Antianemic

Parenteral Iron SupplementAntianemic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Iron isomaltoside consists of iron strongly bound to a chemically modified isomalto-oligosaccharides, theorized to lower immunogenicity due to its linear and unbranched carbohydrate moiety. The strong binding enables a controlled slow release of bioavailable iron.

Indications

iron deficiency anemia in patients with intolerance to oral ironiron deficiency anemia in patients with unsatisfactory response to oral ironiron deficiency anemia in patients with non–dialysis-dependent chronic kidney disease

Dosing

Adult
If weight ≥50 kg: single dose of 1000 mg. If weight <50 kg: single dose of 20 mg/kg. Administer doses up to 1 g over at least 20 min. Administer doses >1 g over at least 30 min. Up to 3 doses of 500 mg can be given over 7 days. 500 mg can be administered as slow IV bolus injection (250 mg/min).

Related guidelines

Other Parenteral Iron Supplement drugs

Ask House about iron isomaltoside

Continue into a citation-backed clinical answer with the drug context already attached.

Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10